



Plot No. 2-B, Sector -126, NOIDA-201304, Distt. Gautam Budh Nagar, Uttar Pradesh, Tel. : +91 120 6860000, 3090100, 3090200 Fax : +91 120 3090111, 3090211 E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

12th November, 2021

The Manager (Listing) BSE Limited 1st Floor, New Trading Ring, Rotunda Building, P.J. Towers, Dalal Street, Mumbai- 400 001

The Manager (Listing) National Stock Exchange of India Limited Exchange Plaza, C- 1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051

Scrip Code: 500201

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Outcome of the Board Meeting held on 12th November, 2021

Further to our letter dated 3rd November, 2021 and pursuant to Regulation 30 and Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e. 12th November, 2021 has, inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2021.

The copy of above results along with the Limited Review Reports of Statutory Auditors thereon is enclosed herewith.

The above said Board Meeting commenced at 15.35 Hrs. and concluded at 17.20 Hrs.

This is for your information and records.

Thanking you,

Yours truly, For **India Glycols Limited**

Anker Jain

Anker Jan Head (Legal) & Company Secretary その Encl: A/a



INDIA GLYCOLS LIMITED

Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand)

Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535

Email: compliance.officer@Indiaglycols.com, Website: www.indiaglycols.com

CIN No.L24111UR1983PLC009097

	ment Of Unaudited Standalone Financial Results for the Quarter & Half	Standalone				(ব in Lakhs	, except as state
			Quarter ended		Half Yea	Year ended	
S.No.	Particulars	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)			
1	Income from operations	(onudanced)	(onauuteu)	(onaddited)	(Unaudited)	(Unaudited)	(Audited)
	(a) Revenue from operations	1,69,463	1,65,165	1,36,278	3,34,628	2,17,855	5,39,00
	(b) Other income	768	258	275	1,026	546	1,20
2	Total income Expenses	1,70,231	1,65,423	1,36,553	3,35,654	2,18,401	5,40,20
-	(a) Cost of materials consumed	39,536	41 777	20.000			
	(b) Purchase of stock-in-trade	9,429	41,777 10,853	28,900	81,313	43,008	1,18,56
	(c) Changes in inventories of finished goods, Stock-in Trade	4,914	(7,375)	7,475	20,282	9,867	30,09
	and work-in-progress	4,514	(7,373)	(3,154)	(2,461)	(6,642)	(1,44
	(d) Excise Duty	91,516	1,00,115	80,602	1 01 691	1 33 013	
	(e) Employee benefits expense	2,470	2,444	2,280	1,91,631 4,914	1,32,912	3,11,04
	(f) Finance Costs	1,480	1,587	1,912	3,067	4,290	8,16
	(g) Depreciation and amortisation expense	1,863	1,897	1,833	3,760	3,668 3,689	7,34
	(h) Power and fuel	7,528	5,535	6,043	13,063	10,634	7,58 21,39
	(i) Other Expenses	7,656	6,260	7,444	13,916	12,300	
	Total Expenses	1,66,392	1,63,093	1,33,335	3,29,485	2,13,726	25,43
	Profit Before Interest, Depreciation and Tax (EBIDTA)	7,182	5,814	6,963	12,996	12,032	26,95
3	Profit / (Loss) from operations before exceptional items and tax (1-2)	3,839	2,330	3,218	6,169	4,675	
4	Exceptional Items (Refer Note 3)		23,988		23,988	4,075	12,03
	Profit / (Loss) before Tax (3+4)	3,839	26,318	3,218	30,157	4,675	12,03
- 1	Tax expense :						
	(a) Current Tax	871	9,647	875	10.518	1,545	1,01
Ì	(b) Deferred Tax	93	(3,875)	(73)	(3,782)	(461)	1,78
	(c) Tax for earlier years	~	*	-		,,	3,03
7	Profit / (Loss) after tax from continuing operations (5-6)	2,875	20,546	2,416	23,421	3,591	6,18
8	Discontinued Operations (Refer Note- 3)						
	Revenue from operations	-	21,407	16,808	21,407	26,095	66.00
-	Total Expenses	_	20,035	15,918	· · · · · · · · · · · · · · · · · · ·		66,80
-	Profit Before Interest, Depreciation and Tax (EBIDTA)				20,035	25,531	62,28
- F	Profit / (Loss) before tax	·····	2,165	2,042	2,165	2,808	8,89
		-	1,372	890	1,372	564	4,51
	Tax Expenses	-	345	224	345	142	2,27
	Profit / (Loss) after tax from discontinued operations	-	1,027	666	1,027	422	2,24:
	Profit / (Loss) for the period (7+8)	2,875	21,573	3,082	24,448	4,013	8,43
	Other Comprehensive Income A (i) Items that will not be reclassified to Profit or Loss	1.00	1,00	10.201	2.00	10	
ľ	(ii) Income tax relating to items that will not be	(0.25)	(0.25)	(0.25) 0.08	2.00 (0.50)	(0.50) 0.16	394 (95
	reclassified to Profit or Loss	, 1	,,		(0.007	0.10	(9)
E	3 (i) Items that will be reclassified to Profit or Loss						
	(ii) Income tax relating to items that will be reclassified to Profit or Loss		-				
	Other Comprehensive Income (Net of Tax)	0.75	0.75	(0.17)	1.50	(0.24)	
11 T	otal comprehensive income / (loss) for the period (9+10)	2,876	21,574	3,082	24,450	(0.34)	295
	Paid-up Equity Share Capital (Face value Rs. 10/- each)	3096	3096	3096	3096	3096	8,725
13 0	Other Equity						309
	arning per equity share (face value of Rs 10/- each) Not						12140
	innualised (in Rs.)						
	a) Continuing Operations - Basic	9.29	66.36	7.80	75.65	11.60	10.0
ľ	- Diluted	9.29	66.36	7.80	75.65		19.9
1	b) Discontinued Operations - Basic	5.23	3.32	2.15	75.65	11.60	19.9
ľ	- Diluted	-		1	1	1.36	7.2
			3,32	2.15	3.32	1.36	7.24
14	c) Continuing & discontinued Operations - Basic	9.29	69.68	9.95	78.97	12.96	27.23
	- Diluted	9.29	69.68	9.95	78.97	12.96	27,23





Unau	dited Segment wise Revenue, Results and Assets and Liabilities	1		Sta	ndalone		(र in Lakhs	
		Quarter ended Half Year of				ar ended Year ended		
S.No.	Particulars	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31,03.2021	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Segment Revenue		- .	1	(onduricu)	Jonadditedj	(Audited)	
	- Bio-based Specialities and Performance Chemicals	55,113	45,732	34,497	1,00,845	50,406	1,49,44	
	- Potable Spirits	1,09,954	1,15,186	98,470	2,25,140	1,60,627	3,74,49	
	- Ennature Biopharma	4,396	4,247	3,311	8,643	6,822	15,06	
	Total	1,69,463	1,65,165	1,36,278	3,34,628	2,17,855	5,39,00	
2	Segment Results (Profit / (Loss) before Interest and Tax)							
	- Bio-based Specialities and Performance Chemicals	3,024	2,109	1,214	5,133	3,302	4,660	
	- Potable Spirits	2,258	2,279	3,936	4,537	6,636	4,00	
	- Ennature Biopharma	1,069	1,061	1,216	2,130	2,726	5,138	
	Total	6,351	5,449	6,366	11,800	12,664	25,15	
	Less /(Add): ~ Interest (Net)				,		23,13	
	- Exceptional Items	1,480	1,587	1,912	3,067	5,636	7,34	
	- Unallocated corporate expenses net of unallocable income	-	(23,988)	~	(23,988)	-	-	
ł		1,032	1,532	1,236	2,564	2,353	5,78;	
	Profit Before Tax from continuing operations	3,839	26,318	3,218	30,157	4,675	12,032	
	Profit/(loss) Before Tax from discontinued operations		1,372	890	1,372	564	4,518	
3	Segment assets							
	- Bio-based Specialities and Performance Chemicals	2,65,322	2,59,021	3,08,848	2,65,322	3,08,848	2,61,124	
	- Potable Spirits	49,257	44,476	42,782	49,257	42,782	52,999	
[- Ennature Biopharma	37,159	39,290	31,141	37,159	31,141	31,744	
	- Unallocated	44,145	42,635	24,439	44,145	24,439	23,281	
	 Assets held for sale and discontinued operations 		-	-		-	38,269	
-	Fotal	3,95,883	3,85,422	4,07,210	3,95,883	4,07,210	4,07,417	
	Segment liabilities							
	 Bio-based Specialities and Performance Chemicals 	98,359	1,01,200	1,26,831	98,359	1,26,831	1,02,105	
	- Potable Spirits	30,620	23,421	25,051	30,620	25,051	34,416	
1	- Ennature Biopharma	7,897	10,630	4,873	7,897	4,873	3,328	
F	- Unallocated	1,11,914	1,04,096	1,30,665	1,11,914	1,30,665	1,39,629	
	Liabilities held for sale and discontinued operations	-	-	-	1	-	3,437	
	otal	2,48,790	2,39,347	2,87,420	2,48,790	2,87,420	2,82,915	





.

Statement of Standalone Unaudited Cash Flows

	Standalone			
De l'autor	Period ended			
Particulars	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)		
Cash Flow from Operating Activities		(onadarica)		
Net Profit/(Loss) Before Tax	30,157	4,675		
Adjustments For:	00,207	-,075		
Depreciation and amortisation expense	3,760	3,689		
(Profit)/Loss on Sale of Property, plant & equipment	(1)	-,		
Net Unrealised Foreign Exchange Fluctuation (Gain) / Loss	(746)	815		
Profit on slump sale of BioEO Business	(23,988)	-		
Provision No Longer Required Written Back	(905)	(70		
Finance Costs	3,193	3,689		
Interest/Dividend Income	(1,152)	(544		
Operating Profit/ (Loss) before Working Capital Changes	10,318	12,260		
Adjustments For:				
(Increase)/Decrease in Trade & Other Receivables	(5,214)	9,555		
(Increase)/Decrease in Inventories	(24)	(12,602		
Increase / (Decrease) in Trade & Other Payables	(7,145)	(8,814		
Cash Generated from / (Used in) Operations	(2,065)	399		
Income Tax Paid (Net)	(733)	(177		
Net Cash flow from / (Used in) Operating Activities	(2,798)	222		
Net Cash flow from / (Used in) discontinued Activities	2,461	2,768		
Net Cash flow from / (Used in) from continuing and discontinued activities	(337)	2,990		
Cash Flow from Investing Activities				
Purchase of Property, plant & equipment	(8,902)	(6,305)		
Sale of Property, plant & equipment	13	17		
Interest/Dividend received	493	16		
ICDs received back	30	-		
Sale consideration received	45,103	-		
Net Cash flow from / (Used in) Investing Activities	36,737	(6,272)		
Net Cash flow from / (Used in) from discontinued activities	(1,668)	(800)		
Net Cash flow from / (Used in) from continuing and discontinued activities	35,069	(7,072)		
Cash Flow from Financing Activities				
Net Proceeds from Borrowings	7,491	12,438		
Repayment of Borrowings	(37,601)	(3,021)		
Payment of lease liabilities	(429)	(236)		
Finance Costs	(3,173)	(2,535)		
Net Cash flow from / (Used in) Financing Activities	(33,712)	6,646		
Net Cash flow from / (Used in) from discontinued activities	(793)	(1,947)		
Net Cash flow from / (Used in) from continuing and discontinued activities	(34,505)	4,699		
Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	227	617		
ter mereure/ weereure/ meuer a euen adairaiente [Privie]	6. fr. f	517		

Opening Cash & Cash Equivalents

Α.

в.

c.

Closing Cash & Cash Equivalents

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard -7, "Statement of Cash Flows".

NEW OELH * RED ACCO

NUTCUTIAN

ତିଠାରେ 1 ିତ <₹. Q 漱

300

527

276

893

(₹ In Lakhs)

Statement of Standalone Unaudited Assets and Liabilities

(₹	In	La	kh	s)

		Standa	
	Particulars	As A 30.09.2021 (Unaudited)	31.03.2021 (Audited)
Α.	ASSETS		
1	Non-current Assets	1.05.154	2 00 44
	 (a) Property, Plant and Equipment (b) Capital work-in-progress 	1,96,164 22,071	2,08,11
	(c) Investment Property	782	11,93 78
	(d) Other Intangible assets	176	18
	(e) Right to use assets	766	1,14
	(f) Financial Assets		-,-
	(i) Investments	2,861	2,86
	(ii) Loans	69	7
	(iii) Others	17,541	4,60
	(g) Other non-current assets	1,615	1,51
	Total Non Current Assets	2,42,045	2,31,22
2	Current Assets		
	(a) Inventories	60,575	60,55
	(b) Financial Assets		
	(i) Trade receivables	45,393	36,47
	(ii) Cash and cash equivalents	527	30
	(iii) Bank balances other than (ii) above	11,895	9,41
	(iv) Loans	8,734 13,331	8,76
	(v) Others (c) Current Tax Assets (Net)	15,551	4,36 1,59
	(d) Other current assets	13,383	16,46
	Total Current Assets	1,53,838	1,37,92
3	Assets held for sale and discontinued operations		38,26
,	Total Assets	3,95,883	4,07,4:
	EQUITY AND LIABILITIES		
L	Equity	3,096	3.00
	 (a) Equity Share capital (b) Other Equity 	1,43,997	3,09 1,21,40
	Total Equity	1,47,093	1,24,50
2	Liabilities		
.1	Non-current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	38,989	50,82
	(ii) Lease Liabilities	334	72
	(iii) Other financial liabilities	3,949	4,21
	(b) Provisions (c) Deferred tax liabilities (Net)	491 28,957	59 32,73
	(d) Others	26,172	26,16
	Total Non-current Liabilities	98,892	1,15,26
	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	35,971	54,20
	(ii) Lease Liabilities	614	65
	(iii) Trade payables	17	1
	total outstanding dues of micro enterprises and small enterprises total outstanding dues of creditors other than micro enterprises and small enterprises	57,739	58,16
	(iv) Other financial liabilities	27,676	24,85
	(b) Other current liabilities	19,020	26,00
	(c) Provisions	324	32
	(d) Current Tax Liabilities (Net)	8,537	
	Total Current Liabilities Liabilities held for sale and discontinued operations	1,49,898	1,64,21
3	Liabilities held for sale and discontinued operations		3,43
	Total Equity and Liabilities	3,95,883	4,07,41
	A NEW DELHI A COUNTIN	S	

Notes:

- 1 The above results were reviewed by the Audit committee in its meeting held on November 12, 2021 and have been approved by the Board of Directors in its meeting held on November 12, 2021. The auditors of the Company have carried out a limited review of the same.
- 2 Financial results have been prepared and presented in accordance with the recognition and measurement principles prescribed under Section 133 of the Companies Act, 2013.
- 3 The Board of Directors of the Company at their meeting held on 24th June, 2020 had considered and approved transfer of Company's BioEO (Speciality Chemicals) Business to a wholly-owned subsidiary, which was further approved by the members of the Company at their Annual General Meeting held on 24th September, 2020. Further, in pursuance to the approval of the Board at their meeting held on 11th March, 2021, the Company had entered into a Business transfer agreement with IGL Green Chemical Private Limited (later on name changed to Clariant IGL Speciality Chemicals Private Limited), a wholly owned subsidiary for transfer of Company's BioEO (Speciality Chemicals) Business to IGCPL and in the same meeting , the Board of Directors of the Company had also approved entering into a joint venture with IGCPL and Clariant International Ltd. The members of the Company had also approved the same by way of a Special Resolution through Postal Ballot effective 25th April, 2021.

The aforesaid transaction meets the criteria prescribed in Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" to be considered as discontinued operation, hence 'BioEO (Speciality Chemicals) Business' has been disclosed as discontinued operations in Standalone financial results. Accordingly, all previous periods figures in the financial results have also been restated. The income, expenses & profitability of discontinuing operations are disclosed in standalone financial results.

The company has transferred 'BioEO (Speciality Chemicals) Business' (specified assets and liabilities including dedicated employees, contracts, licenses, permits, consents, approvals and other legal documents relating to the said business) to IGL Green Chemicals Private Limited (later on name changed to Clariant IGL Specialty Chemicals Private Limited), a wholly owned subsidiary (in accordance with the term of the BTA) with effect from 30 June 2021 as a going concern for a lump sum consideration of Rs 65222 Lakhs (subject to reconciliation /adjustment of working capital & others) by way of slump sale (Rs 45103 Lakhs has been received till 30th September, 2021 and balance will be received over a period of 3 years) and recognised gain of Rs 23988 Lakhs (net of BTA expenses) on slump sale of said business (subject to reconciliation /adjustment of working capital & others), which has been disclosed as exceptional items in previous quarter standalone financial results.

- Further, pursuant to the terms of the JVA and the approvals of the members granted on 25 April 2021, and upon fulfilment of conditions precedent as identified under the JVA, on 30 June 2021, Clariant has invested Rs 58774 Lakhs in the IGCPL, and the IGCPL has allotted and issued 11,240 equity shares (having a face value of Rs 10/-each) @ Rs. 5,22,905 per share (which includes a premium of Rs. 5,22,895 per share) to Clariant International Ltd., such that the IGCPL has become a 51:49 Joint Venture company, in which 51% stake has been held by Clariant International Ltd. and the remaining 49% stake held by the company along with its wholly owned subsidiary.
- 4 The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets and it has also taken into account the future cash flows. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration.
- 5 Since 1989, there has been a huge shift in industry scenario, products, market dynamics, drivers, technologies as well as the demand of the company's products. The company has therefore evolved quite significantly, expanding into a wide range of synergistic portfolios building on the company's capabilities and responding to the market needs. Considering the same and to represent all its segment in the current context, the company is changing the names of all the segments from Industrial Chemicals, Ethyl Alcohol (Potable) & Nutraceutical to Bio-based Specialities and Performance Chemicals, Potable Spirits & Ennature Biopharma respectively.
- 6 Subsequent of the current quarter, pursuant to the approval of Board of directors and shareholders of the company, the Company has incorporated a wholly owned subsidiary named Ennature Biopharma Private Limited. Decision for transfer of the Ennature Biopharma business will be taken at an appropriate time by Board of Directors.
- 7 The figures of the previous period/year have been restated/regrouped wherever necessary, to make them comparable.


Place : Dehradun Date : 12th November, 2021



OLS

for INDIA GLYCOLS LIMITED

U.S. BHARTIA Chairman and Managing Director DIN: 00063091



Limited review report on unaudited quarterly and year-to-date standalone financial results of India Glycols Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF INDIA GLYCOLS LIMITED

- We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of India Glycols Limited ("the company") for the quarter ended 30th September, 2021 and year to date results for the period from 1st April, 2021 to 30th September, 2021 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind As 34") prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR K.N. GUTGUTIA & CO. CHARTERED ACCOUNTANTS FRN 304153E

Marin

(B.R. GOYAL) PARTNER M.NO. 12172 UDIN : 21012172AAABRL2931 DATED: 12TH NOVEMBER, 2021 PLACE : NEW DELHI





INDIA GLYCOLS LIMITED

Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand) Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535

Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com

CIN No.L24111UR1983PLC009097

Stat	ement Of Consolidated Unaudited Financial Results for the Quarter & Ha	If Year ended	September 30,	2021		(₹ In Lakhs,	except as stated
			Quarter ended	ł	Half Yea	ar ended	Year ended
S.N	Particulars	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	(a) Revenue from operations	1,69,529	1,65,182	1,36,645	3,34,711	2,18,231	5,42,747
	(b) Other income Total income	839 1,70,368	133	222 1,36,867	972 3,35,683	367 2,18,598	1,526 5,44,273
2	Expenses	1,70,500	1,00,010	1,50,807	3,33,003	2,10,550	5,44,275
	(a) Cost of materials consumed	39,536	41,777	28,900	81,313	43,008	1,18,560
	(b) Purchase of stock-in-trade	9,473	10,853	7,842	20,326	10,234	32,827
	(c) Changes in inventories of finished goods, Stock-in Trade	4,914	(7,375)	(3,154)	(2,461)	(6,642)	(1,470
	and work-in-progress	· -				(-,,	(-,
	(d) Excise Duty	91,516	1,00,115	80,602	1,91,631	1,32,912	3,11,048
	(e) Employee benefits expense	2,507	2,485	2,317	4,992	4,374	8,333
	(f) Finance Costs	1,672	1,767	2,088	3,439	4,011	8,338
	(g) Depreciation and amortisation expense	1,966	2,000	1,942	3,966	3,906	8,012
	(h) Power and fuel	7,528	5,535	6,043	13,063	10,634	21,393
	(i) Other Expenses	7,442	6,298	7,477	13,740	12,364	25,256
	Total Expenses	1,66,554	1,63,455	1,34,057	3,30,009	2,14,801	5,32,297
	Profit Before Interest, Depreciation and Tax (EBIDTA)	7,452	5,627	6,840	13,079	11,714	28,326
3	Profit / (Loss) from operations before exceptional items and tax (1-2)	3,814	1,860	2,810	5.674	3,797	11,976
4	Exceptional Items (Refer Note - 3)	-	23,988		23,988		-
5	Profit / (Loss) before Tax (3+4)	3,814	25,848	2,810	29,662	3,797	11,976
6	Share of net profit/ (loss) of Joint Ventures	878	45	(19)	923	(54)	72
7	Profit / (Loss) before Tax (5+6)	4,692	25,893	2,791	30,585	3,743	12,048
8	Tax expense :						
	(a) Current Tax	871	9,647	875	10,518	1,545	1,016
	(b) Deferred Tax	93	(3,875)	(73)	(3,782)	(461)	(820)
	(c) Tax for earlier years		(3,873)	(73)	(3,762)	(401)	932
9	Profit / (Loss) after tax from continuing operations (7-8)	3,728	20,121	1,989	23,849	2,659	10,920
10	Discontinued Operations (Refer Note- 3)						
10				46.000			
	Revenue from operations	-	21,407	16,808	21,407	26,095	. 66,807
	Total Expenses	-	20,035	15,918	20,035	25,531	62,289
	Profit Before Interest, Depreciation and Tax (EBIDTA)		2,165	2,042	2,165	2,808	8,896
	Profit / (Loss) before tax	-	1,372	890	1,372	564	4,518
	Tax Expenses	-	345	224	345	142	2,277
	Profit / (Loss) after tax from discontinued operations	-	1,027	666	1,027	422	2,241
11	Profit / (Loss) for the period (9+10)	3,728	21,148	2,655	24,876	3,081	13,161
12	Other Comprehensive Income	1 00	1.00	(0.05)	0.00	10 10	
	A (i) Items that will not be reclassified to Profit or Loss	1.00 (0.25)	1.00 (0.25)	(0.25) 0.08	2.00 (0.50)	(0.50) 0.16	394
	 (ii) Income tax relating to items that will not be reclassified to Profit or Loss 	(0.25)	(0.23)	0.08	(0.50)	0.10	(99)
	B (i) Items that will be reclassified to Profit or Loss	(14)	0.49	15	(13)	15	10
	(ii) Income tax relating to items that will be		-				
	reclassified to Profit or Loss	(13)	1.24	15	(12)	15	305
10	Other Comprehensive Income (Net of Tax)	3,715	21,149				
13	Total comprehensive income / (loss) for the period (11+12)	5,715	LI,149	2,670	24,864	3,096	13,466





14	Net Profit/ (Loss) attributable to (a) Owners of the Company (b) Non Controlling interest	3,728	21,148	2,655	24,876	3,081	13,161
	Other Comprehensive Income attributable to (a) Owners of the Company (b) Non Controlling interest	(13)	1.24	15	(12)	15	305
16	Total Comprehensive Income attributable to (a) Owners of the Company (b) Non Controlling interest	3,715	21,149	2,670	24,864	3,096	13,466
17	Paid-up Equity Share Capital (Face value Rs. 10/- each)	3,096	3,096	3,096	3.096	3,096	3,096
18	Other Equity						1,13,756
19	Earning per equity share (face value of Rs 10/- each) Not annualised (in Rs.)						
	(a) Continuing Operations - Basic	12.04	64.99	6.42	77.03	8.59	35.27
	- Diluted	12.04	64.99	6.42	77.03	8.59	35.27
	(b) Discontinued Operations - Basic	-	3.32	2.15	3.32	1.36	7.24
	- Diluted	-	3.32	2.15	3.32	1.36	7,24
	(c) Continuing & discontinued Operations - Basic	12.04	68.30	8.58	80.35	9.95	42.51
	- Diluted	12.04	68.30	8.58	80.35	9.95	42.51

Consolidated Unaudited Segment wise Revenue, Results and Assets and Liabilities

		Quarter ended			Half Yea	Year ended	
5.N	Particulars	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	- Bio-based Specialities and Performance Chemicals	55,179	45,749	34,864	1,00,928	50,782	1,53,188
	- Potable Spirits	1,09,954	1,15,186	98,470	2,25,140	1,60,627	3,74,499
	- Ennature Biopharma	4,396	4,247	3,311	8,643	6,822	15,06
	Total	1,69,529	1,65,182	1,36,645	3,34,711	2,18,231	5,42,74
2	Segment Results (Profit / (Loss) before Interest and Tax)						
	- Bio-based Specialities and Performance Chemicals	3,328	1,960	1,049	5,288	1,005	6,623
	- Potable Spirits	2,258	2,279	3,936	4,537	6,636	15,36
	- Ennature Biopharma	1,069	1,061	1,216	2,130	2,726	5,138
	Total	6,655	5,300	6,201	11,955	10,367	27,122
	Less /(Add): - Interest (Net) - Exceptional Items	1,672	1,767 (23,988)	2,088	3,439 (23,988)	4,011	8,338
	- Unallocated corporate expenses net of unallocable income	1,169	1,673	1,303	2,842	2,559	- 6,808
	Profit before share of profit / (Loss) from joint venture and exceptional	3,814	25,848	2,810	29,662	3,797	11,976
	items			2,010		3,737	11,970
	Share of profit/(loss) of Joint Venture	878	45	(19)	923	(54)	72
	Profit Before Tax from continuing operations	4,692	25,893	2,791	30,585	3,743	12,048
	Profit/(loss) Before Tax from discontinued operations		1,372	890	1,372	564	4,518
3	Segment assets						
	- Bio-based Specialities and Performance Chemicals	2,75,334	2,68,956	3,18,988	2,75,334	3,18,988	2,71,558
	- Potable Spirits	49,257	44,476	42,782	49,257	42,782	52,999
	- Ennature Biopharma	37,159	39,290	31,141	37,159	31,141	31,744
	- Unallocated	67,832	65,435	19,667	67,832	19,667	17,354
	- Assets held for sale and discontinued operations	-	-	-			38,269
	Total	4,29,582	4,18,157	4,12,578	4,29,582	4,12,578	4,11,924
1	Segment liabilities						
	- Bio-based Specialities and Performance Chemicals	98,596	1,01,507	1,29,365	98,596	1,29,365	1.02.736
	- Potable Spirits	30,620	23,421	25,051	30,620	25,051	34,416
	- Ennature Biopharma	7,896	10,630	4,873	7,896	4,873	3,328
	- Unallocated	1,23,812	1,15,795	1,46,807	1,23,812	1,46,807	1,51,155
	- Liabilities held for sale and discontinued operations	-	- [3,437
	Total	2,60,924	2,51,353	3,06,096	2,60,924	3,06,096	2,95,072



COLS ŝ Ô L. Ĉ N *

Statement of Consolidated Unaudited Cash Flows

		Consolidated			
	Particulars	Period ended 30.09.2021 30.09			
		(Unaudited)	30.09.2020 (Unaudited)		
A. Ca	ish Flow from Operating Activities				
1	et Profit/(Loss) Before Tax	29,662	3,7		
	ljustments For:				
	epreciation and amortisation expense	3,966	3,9		
	rofit)/Loss on Sale of Property, plant & equipment	(1)			
	et Unrealised Foreign Exchange Fluctuation (Gain) / Loss	(746)	8		
	ovt Grant (Net)	~	-		
1	ofit on slump sale of BioEO Business	(23,988)	-		
	ovision No Longer Required Written Back	(905)	(
	hance Costs	3,567	4,3		
	erest/Dividend Income	(893)			
	erating Profit/ (Loss) before Working Capital Changes	10,662	12,1		
Adj	justments For:				
(Inc	crease)/Decrease in Trade & Other Receivables	(5,151)	9,6		
(Inc	crease)/Decrease in Inventories	44	(12,6		
Inci	rease / (Decrease) in Trade & Other Payables	(7,549)	(8,8		
Cas	sh Generated from / (Used in) Operations	(1,994)	4		
Inco	ome Tax Paid (Net)	(733)	(1)		
Net	t Cash flow from / (Used in) Operating Activities	(2,727)			
Net	t Cash flow from / (Used in) from discontinued activities	2,461	2,70		
	t Cash flow from / (Used in) from continuing and discontinued activities	(266)	3,0:		
Cas	h Flow from Investing Activities				
Pure	chase of Property, plant & equipment	(8,902)	(6,37		
Sale	e of Property, plant & equipment	13	(-,		
Inte	erest/Dividend received	470	26		
ICD	s received back	30	-		
Sale	e consideration received	45,103	-		
Net	Cash flow from / (Used in) Investing Activities	36,714			
	Cash flow from / (Used in) from discontinued activities	(1,668)	(6,08		
	Cash flow from / (Used in) from continuing and discontinued activities	35,046	(80)(6,88		
Cast	h Flow from Financing Activities				
Net	Proceeds from Borrowings	7,491	12,43		
Repa	ayment of Borrowings	(37,601)			
	ment of lease liabilities	(429)	(3,02		
1	nce Costs	(3,176)	(23)		
Net	Cash flow from / (Used in) Financing Activities	(33,715)	(2,78		
1	Cash flow from / (Used in) from discontinued activities		6,390		
	Cash flow from / (Used in) from continuing and discontinued activities	(793)	(1,94)		
	Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	(34,508) 272	4,449		
Oner	ning Cash & Cash Fourivalant				
lober	ning Cash & Cash Equivalent	339	365		

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard -7, "Statement of Cash Flows".

NEWPELH

MARED ACCOUNT

<u>(000)</u> ିତ FOLA -*

Statement of Consolidated Unaudited Assets and Liabilities

	Concolid	(₹ in Lakh:
	Consolid As At	
Particulars	30.09.2021	31.03.2021
	(Unaudited)	(Audited)
A. ASSETS		f
1 Non-current Assets		
(a) Property, Plant and Equipment	2,04,982	0 177 104
(b) Capital work-in-progress	22,709	2,17,134
(c) Investment Property	782	12,577
(d) Other Intangible assets	176	789
(e) Right to use assets		187
(f) Investments in Joint Venture	766	1,149
(g) Financial Assets	32,429	2,707
(i) Loans		
(ii) Others	69	74
(h) Other non-current assets	17,713	4,772
Total Non Current Assets	1,615	1,511
	2,81,241	2,40,900
Current Assets		
(a) Inventories	60,931	ca a=-
(b) Financial Assets	00,951	60,975
(i) Trade receivables		
(ii) Cash and cash equivalents	45,035	36,172
(iii) Bank balances other than (ii) above	611	339
(iv) Loans	11,895	9,415
(v) Others	2,518	2,548
(c) Current Tax Assets (Net)	13,880	5,150
(d) Other current assets	11	1,605
	13,460	16,551
Total Current Assets	1,48,341	1,32,755
Assets held for sale and discontinued operations		
Total Assets	A 20 - 200	38,269
	4,29,582	4,11,924
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	3,096	3,096
(b) Other Equity	1,65,562	1,13,756
Total Equity	1,68,658	1,16,852
Liabilities	2,00,038	1,10,852
Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	20.000	
(ii) Lease Liabilities	38,989	50,822
(iii) Other financial liabilities	334	727
(b) Provisions	3,951	4,243
(c) Deferred tax liabilities (Net)	491	595
(d) Others	31,962	35,744
Total Non-current Liabilities	26,172	26,167
Current Liabilities	1,01,899	1,18,298
(a) Financial Liabilities		
(i) Borrowings		
(ii) Lease Liabilities	43,246	61,478
(iii) Trade payables	614	650
total outstanding dues of micro enterprises and small enterprises		
	17	18
total outstanding dues of merid enterprises and small enterprises	57,482	58,060
total outstanding dues of creditors other than micro enterprises and small enterprises		26,517
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities	29,594	
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities		26 28a i
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions	19,209	26,289
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current Tax Liabilities (Net)	19,209 327	26,289 325
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current Tax Liabilities (Net) Total Current Liabilities	19,209 327 8,536	325
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current Tax Liabilities (Net)	19,209 327	325 - 1,73,337
total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current Tax Liabilities (Net) Total Current Liabilities	19,209 327 8,536	325





Notes:

- 1 The above results were reviewed by the Audit committee in its meeting held on November 12, 2021 and have been approved by the Board of Directors in its meeting held on November 12, 2021. The auditors of the Company have carried out a limited review of the same.
- 2 Financial results have been prepared and presented in accordance with the recognition and measurement principles prescribed under Section 133 of the Companies Act, 2013.
- 3 The Board of Directors of the parent Company at their meeting held on 24th June, 2020 had considered and approved transfer of parent Company's BioEO (Speciality Chemicals) Business to a wholly-owned subsidiary, which was further approved by the members of the parent Company at their Annual General Meeting held on 24th September, 2020. Further, in pursuance to the approval of the Board at their meeting held on 11th March, 2021, the parent Company had entered into a Business transfer agreement with IGL Green Chemical Private Limited (later on name changed to Clariant IGL Specialty Chemicals Private Limited), a wholly owned approved entering into a joint venture with IGCPL and Clariant International Ltd. The members of the parent Company had also approved the same by way of a Special Resolution through Postal Ballot effective 25th April, 2021.

The aforesaid transaction meets the criteria prescribed in Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" to be considered as discontinued operation, hence 'BioEO (Speciality Chemicals) Business' has been disclosed as discontinued operations in Consolidated financial results. Accordingly, all previous periods figures in the financial results have also been restated. The income, expenses & profitability of discontinuing operations are disclosed in consolidated financial results.


The parent company has transferred 'BioEO (Speciality Chemicals) Business' (specified assets and liabilities including dedicated employees, contracts, licenses, permits, consents, approvals and other legal documents relating to the said business) to IGL Green Chemical Private Limited (later on name changed to Clariant IGL Specialty Chemicals Private Limited), a wholly owned subsidiary (in accordance with the term of the BTA) with effect from 30 June 2021 as a going concern for a lump sum consideration of Rs 65222 Lakhs (subject to reconciliation /adjustment of working capital & others) by way of slump sale (Rs 45103 Lakhs has been received till 30th September, 2021 and balance will be received over a period of 3 years) and recognised gain of Rs 23988 Lakhs (net of BTA expenses) on slump sale of said business (subject to reconciliation /adjustment of working capital & others), which has been disclosed as exceptional items in previous quarter consolidated financial results.

Further, pursuant to the terms of the JVA and the approvals of the members granted on 25 April 2021, and upon fulfilment of conditions precedent as identified under the JVA, on 30 June 2021, Clariant has invested Rs 58774 Lakhs in the IGCPL, and the IGCPL has allotted and issued 11,240 equity shares (having a face value of Rs 10/-each) @ Rs. 5,22,905 per share (which includes a premium of Rs. 5,22,895 per share) to Clariant International Ltd., such that the IGCPL has become a 51 :49 Joint Venture company, in which 51% stake has been held by Clariant International Ltd. and the remaining 49% stake has been held by the parent company along with its wholly owned subsidiary and hence, consolidation of IGCPL has been done accordingly.

- 4 The Group has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets and it has also taken into account the future cash flows. On the basis of evaluation and current indicators of future economic conditions, the Group expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration.
- 5 Since 1989, there has been a huge shift in industry scenario, products, market dynamics, drivers, technologies as well as the demand of the parent company's products. The parent company has therefore evolved quite significantly, expanding into a wide range of synergistic portfolios building on the parent company's capabilities and responding to the market needs. Considering the same and to represent all its segment in the current context, the parent company is changing the names of all the segments from Industrial Chemicals, Ethyl Alcohol (Potable) & Nutraceutical to Bio-based Specialities and Performance Chemicals, Potable Spirits & Ennature Biopharma respectively
- 6 Subsequent of the current quarter, pursuant to the approval of Board of directors and shareholders of the parent company, the parent Company has incorporated a wholly owned subsidiary named Ennature Biopharma Private Limited. Decision for transfer of the Ennature Biopharma business will be taken at an appropriate time by Board of Directors.
- 7 The figures of the previous period/year have been restated/regrouped wherever necessary, to make them comparable.

Place : Dehradun Date : 12th November, 2021

WINNIN WINNIN GUTZ 会 NEW DEL ED ACCO **Ummin**



for INDIA GLYCOLS LIMITED

U.S. BHARTIA Chairman and Managing Director DIN: 00063091

 K.N. GUTGUTIA & CO.		11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
 CHARTERED ACCOUNTANTS		Phones : 25713944, 25788644, 25818644
NEW DELHI : KOLKATA		E-mail : brg1971@cakng.com, kng1971@yahoo.com Website : www.cakng.com

Limited review report on unaudited quarterly and year-to-date consolidated financial results of India Glycols Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

то


THE BOARD OF DIRECTORS OF INDIA GLYCOLS LIMITED

- 1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of India Glycols Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of the net Profit after tax and total comprehensive Income of its joint ventures for the quarter ended 30th September, 2021 and year to date results for the period from 1st April, 2021 to 30th September, 2021 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 5. The Statement includes the results of the following entities:

Subsidiaries

- i) Shakumbari Sugar And Allied Industries Limited (SSAIL)
- ii) IGL Finance Limited
- iii) IGL Chem International PTE LTD
- iv) IGL Chem International USA LLC
- v) IGL Chemicals and Services Private Limited.





11-K, GOPALA TOWER, 25, RAJENDRA PLACE; **NEW DELHI-110008** Phones: 25713944, 25788644, 25818644 E-mail : brg1971@cakng.com, kng1971@yahoo.com

Joint Ventures

- i) Kashipur Infrastructure and Freight Terminal (Pvt.) Ltd.
- ii) Clariant IGL Specialty Chemicals Private Limited (formerly known as IGL Green Chemicals Private Limited)
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 7. The consolidated unaudited financial results includes the Group's share of net profit after tax of Rs. 830.50 lakhs and total comprehensive income of Rs. 830.50 lakhs for the guarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021 respectively, as considered in the Statement, in respect of a joint venture, whose interim financial information / financial result has not been reviewed by us. This interim financial information/ financial result has been reviewed by another auditor whose report has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this joint venture, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 and 4 above.

Our conclusion on the Statement is not modified in respect of this matter.

FOR K.N. GUTGUTIA & CO. CHARTERED ACCOUNTANTS FRN 304153E

Barnie

(B.R. GOYAL) PARTNER M.NO. 12172 UDIN: 21012172AAABRM8565 DATED: 12TH NOVEMBER, 2021 PLACE : NEW DELHI

